Pivotal Trial
A Phase III clinical trial whose results form the primary basis for a regulatory approval application. Pivotal trials must be well-controlled, adequately powered, and demonstrate clinically meaningful efficacy with an acceptable safety profile. Most drugs require at least two pivotal trials for approval.
Technical Context
Pivotal trials are designed in close consultation with regulatory agencies (pre-IND meetings with FDA, scientific advice from EMA). Key pre-specifications include: primary endpoint, statistical hypothesis, sample size justification, analysis population, handling of missing data, multiplicity adjustment, and subgroup analyses. Results must demonstrate both statistical significance and clinical meaningfulness. For new indications of approved drugs (e.g. semaglutide for weight management), a new pivotal programme is required even though the drug is already approved for another indication. Pivotal trial data form the core of regulatory submissions (NDA/BLA/MAA) and are the primary basis for the benefit-risk assessment that determines approval.